Disc Medicine terminates at-the-market sales agreement with Leerink Partners

Disc Medicine, Inc.

Terminated the Sales Agreement dated January 25, 2023, effective September 28, 2023.
No termination penalties incurred; no shares sold under the agreement since June 12, 2023.
Company retains ability to seek alternative equity financing arrangements.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Disc Medicine, Inc. terminated Sales Agreement with Leerink Partners LLC (f/k/a SVB Securities LLC) valued at Termination of Sales Agreement without penalties (effective 2023-09-28).

Action: termination
Agreement: atm program
Counterparty: Leerink Partners LLC (f/k/a SVB Securities LLC)
Value: Termination of Sales Agreement without penalties
Effective: 2023-09-28

Exact text from the filing

On September 20, 2023, the Company delivered written notice to Leerink Partners LLC (f/k/a SVB Securities LLC) ("Leerink") that it was terminating the Sales Agreement dated January 25, 2023 (the "Sales Agreement"), by and between the Company and Leerink, in accordance with its terms, which termination became effective on September 28, 2023.

View on SEC.gov

Browse all material agreements →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-247379

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.